Humana issues national coverage policy for Barostim neuromodulation therapy

Humana has issued a new Medicare coverage policy for Barostim neuromodulation therapy, a device-based treatment for resistant hypertension. The policy establishes national coverage criteria and sets the stage for claims adjudication. The move follows a CMS pricing decision for similar cardiac monitoring technologies, indicating payer focus on novel device reimbursement. For practices offering this therapy, confirm that Humana's clinical criteria match your patient selection protocols and prepare for potential pre-authorization requirements. Monitor for analogous coverage announcements from other major payers in the coming weeks.